EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Endometrial prostaglandin F release in vitro and plasma 13,14-dihydro-15-keto-prostaglandin F2 alpha in pigs with luteolysis blocked by pregnancy, estradiol benzoate or human chorionic gonadotropin



Endometrial prostaglandin F release in vitro and plasma 13,14-dihydro-15-keto-prostaglandin F2 alpha in pigs with luteolysis blocked by pregnancy, estradiol benzoate or human chorionic gonadotropin



Journal of Animal Science 52(2): 330-339



Experiments were conducted to determine whether the plasma PGF2 alpha metabolite 13, 14-dihydro-15-keto- PGF (PGFM), increases during luteolysis and whether pregnancy or oestradiol benzoate (EB) or HCG treatment would prevent increased endometrial PGF release in vitro and increased plasma PGFM. In the 1st experiment, endometrial and luteal tissue was recovered 16 days after the onset of oestrus from 27 mature gilts in 4 treatment groups: (1) non-pregnant (non-inseminated); (2) pregnant; (3) non-pregnant, given 10 mg of EB on day 12 of the cycle, and (4) non-pregnant, given 1000 IU of HCG on day 12 of the cycle. Duplicate samples of luteal and endometrial tissue (circa 100 mg) were incubated in Krebs Ringer bicarbonate buffer for 2 h in (1) air at 0 deg C, (2) an atmosphere of 95% O2:5% CO2 at 37 deg C, or (3) same as (2), but with 1.3 X 10-4M indomethacin added. Hormones were quantified by radioimmunoassay. Progesterone in plasma and progesterone release in vitro from luteal tissue collected on day 16 indicated that pregnancy, EB and HCG blocked luteolysis. The PGF release from endometrial tissue incubated in vitro at 37 deg C was less when tissue was from pregnant and EB-treated pigs (P<0.05) than when it was from non-pregnant pigs (47.1 and 36.7 vs. 80.2 ng per 100 mg tissue); the mean for tissue from HCG-treated pigs (68.6 ng per 100 mg tissue), was not significantly different from the means from pigs in the other treatment groups. The PGF release from luteal tissue in vitro was not significantly affected by pig treatment. In a 2nd experiment, 15 pigs assigned to treatment groups identical to those in the 1st experiment were bled once daily from days 12 to 20 for quantification of progesterone and PGFM in plasma. Progesterone in plasma from HCG-treated pigs increased from 33.3 ng per ml on day 12 to 61.8 and 72.5 on days 16 and 17 resp. (P<0.05), and the means for days 16 and 17 were greater (P<0.01) than those for the other treatment groups. In non-pregnant pigs, PGFM in plasma increased from 164 pg per ml on day 12 to 1249 pg per ml on days 14 to 17, at which time progesterone concentrations were 10% of those on day 12. PGFM in plasma was lower on days 13 and 14 in pregnant and EB-treated pigs than in non-pregnant and HCG-treated pigs (P<0.01). The increase in PGFM in plasma during the time corresponding to the late luteal phase in non-pregnant pigs was completely blocked by pregnancy or by EB or HCG treatment; PGFM concentration in plasma was rarely higher than 300 pg per ml in treated pigs. Oestrogen treatment or pregnancy may exert an anti-luteolytic effect in pigs by reducing the uterine secretion of PGF2 alpha ; this possibility is consistent with the hypothesis that oestrogen secretion by blastocysts initiates the maternal recognition of pregnancy in pigs.

(PDF emailed within 1 workday: $29.90)

Accession: 000878202

Download citation: RISBibTeXText

PMID: 7275859



Related references

Effect of pregnancy, estradiol benzoate (EB), or human chorionic gonadotropin (HCG) on secretion of prostaglandin (PG)F in vitro and 13,14-dihydro-15-keto-PGF (PGFM) in vivo in the pig. 9th International Congress on Animal Reproduction and Artificial Insemination, 16th-20th June 1980 III Symposia free communications: 152, 1980

Changes in plasma estrogen, luteinizing hormone, follicle-stimulating hormone and 13,14-dihydro-15-keto-prostaglandin F2 alpha during blockade of luteolysis in pigs after human chorionic gonadotropin treatment. Journal of Animal Science 57(4): 993-1000, 1983

Changes in plasma estrogen, luteinizing hormone, follicle-stimulating hormone and 13,14-dihydro-15-keto-prostaglandin F2a during blockade of luteolysis in pigs after human chorionic gonadotropin treatment. Journal of Animal Science 57: 3-1000, 1983

Peripheral plasma concentrations of 13,14-dihydro-15-keto-prostaglandin F2 alpha and progesterone around luteolysis and during early pregnancy in the goat. Prostaglandins 24(3): 313-321, 1982

Effects of prostaglandins di butyryl cyclic amp lhrh estrogens progesterone and potassium on output of prostaglandin f 2 alpha 13 14 di hydro 15 keto prostaglandin f 2 alpha human chorionic gonadotropin estradiol and progesterone by placental minces. Prostaglandins 24(4): 495-506, 1982

Human chorionic gonadotropin induced prostaglandin e 2 and prostaglandin f 2 alpha release in adult rat testis role in leydig cell de sensitization to human chorionic gonadotropin. Life Sciences 24(23): 2151-2158, 1979

Simultaneous determination of ovarian prostaglandin e 2 prostaglandin f 2 alpha 6 ketoprostaglandin f 1 alpha beta estradiol and progesterone during ovulation in the pregnant mare serum gonadotropin human chorionic gonadotropin primed immature rat. Biology of Reproduction 34(SUPPL 1): 125, 1986

Amniotic fluid concentrations of prostaglandin F2 alpha, 13,14-dihydro-15-keto-prostaglandin F2 alpha (PGFM) and 11-deoxy-13,14-dihydro-15-keto-11, 16-cyclo-prostaglandin E2 (PGEM-LL) in preterm labor. Prostaglandins 37(1): 149-161, 1989

Mechanism of luteolysis: effect of estradiol and prostaglandin F2 alpha on corpus luteum luteinizing hormone/human chorionic gonadotropin receptors and cyclic nucleotides in the rhesus monkey. American Journal of Obstetrics and Gynecology 139(2): 134-140, 1981

Plasma prostaglandin F2 alpha and plasma 13,14-dihydro-15-keto-prostaglandin F2 alpha levels in women during induction of labor with i.v. infusion of prostaglandin F2 alpha in relation to uterine contractions. Journal of Perinatal Medicine 13(1): 15-21, 1985

Dose effect of human chorionic gonadotropin on plasma progesterone estrogen and 13 14 di hydro 15 keto prostaglandin f 2 alpha in the pig. Biology of Reproduction 24(SUPPL 1): 97A, 1981

6-Keto prostaglandin F1 alpha, thromboxane B2, and 13,14-dihydro-15-keto prostaglandin F concentrations of normotensive and preeclamptic patients during pregnancy, delivery, and the postpartum period. American Journal of Obstetrics and Gynecology 151(1): 121-127, 1985

Elevated concentrations of 13,14-dihydro-15-keto-prostaglandin F-2 alpha in maternal plasma during prepartum luteolysis and parturition in dogs (Canis familiaris). Journal of Reproduction and Fertility 84(1): 71-77, 1988

Measurement of 13,14-dihydro-15-keto-prostaglandin F2 alpha and 6-keto-prostaglandin F1 alpha in plasma by radioimmunoassay without prior extraction or chromatography. Prostaglandins, Leukotrienes, and Medicine 9(5): 491-493, 1982